D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.
about
Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disordersVirtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptabilityPharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disordersPTSD: from neurobiology to pharmacological treatmentsEmerging drugs for the treatment of anxietyD-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trialFear-Potentiated Startle and Fear Extinction in a Sample of Undergraduate Women Exposed to a Campus Mass Shooting.GABA and NMDA receptors in CRF neurons have opposing effects in fear acquisition and anxiety in central amygdala vs. bed nucleus of the stria terminalis.An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical TrialsConditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviorsA randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.The Use of Virtual Reality to Facilitate Mindfulness Skills Training in Dialectical Behavioral Therapy for Borderline Personality Disorder: A Case Study.Feasibility of articulated arm mounted Oculus Rift Virtual Reality goggles for adjunctive pain control during occupational therapy in pediatric burn patientsOpposing effects of D-cycloserine on fear despite a common extinction duration: interactions between brain regions and behavior.Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.On the resilience of remote traumatic memories against exposure therapy-mediated attenuation.D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial.NMDA receptor activation regulates sociability by its effect on mTOR signaling activity.Psychopharmacological strategies in the management of posttraumatic stress disorder (PTSD): what have we learned?Investigational drugs under development for the treatment of PTSD.Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.Modulating fear extinction memory by manipulating SK potassium channels in the infralimbic cortex.An empirical review of potential mediators and mechanisms of prolonged exposure therapy.Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress.The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders.Sleep Disturbance in Posttraumatic Stress Disorder: Epiphenomenon or Causal Factor?Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.On the Road to Translation for PTSD Treatment: Theoretical and Practical Considerations of the Use of Human Models of Conditioned Fear for Drug Development.Integrating NIMH Research Domain Criteria (RDoC) into PTSD Research.Genome-wide gene-based analysis suggests an association between Neuroligin 1 (NLGN1) and post-traumatic stress disorder.Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction.Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial.Optimizing the efficacy of exposure in PTSD treatment.Positive effects of the traditional Chinese medicine MLC901 in cognitive tasks.Review of Virtual Reality Treatment in Psychiatry: Evidence Versus Current Diffusion and Use.Clinical Virtual Reality tools to advance the prevention, assessment, and treatment of PTSD.Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial.Selectively Bred Rats Provide a Unique Model of Vulnerability to PTSD-Like Behavior and Respond Differentially to FGF2 Augmentation Early in Life.
P2860
Q24187995-D36BB87A-1B25-4972-B9DE-A271FA85F61CQ26778474-AF5F7FE8-FC5E-4E61-BB5F-977EC57DE24BQ27006437-C1DA3E19-9BDD-49AC-9FF0-0843B24E911BQ28070159-1CA6153B-4CBC-422B-8AA9-002E9A44B62FQ28083141-DF1BD9C0-FB5B-4EFC-8BA3-F9BAB6C44EADQ28396812-7CA1B3D9-FF63-4AEE-A38F-80A4F64DD975Q30365336-B6CDB44A-7C2D-4243-8935-7AC2497922D9Q30370972-DE53FEB9-E3CB-47E6-9337-9A5EBF095488Q30375098-D877DBD6-CCC0-4AE7-9F91-D384E863F78EQ30433318-F4F17507-AAED-458D-A552-14878E8D54ADQ30585383-1A0CA83C-1AE2-42CD-AF31-F64CC8062D46Q30695515-2C02379E-29FA-4273-B177-266BC116FAE9Q30827060-D1159232-DD5E-4E61-B53C-3CC262B09E12Q33705314-1A1DB195-F3C9-4A65-BE13-3F151008FA28Q33740875-99AE1819-71D8-43BC-8104-5320C70F9104Q34017493-7F2A9F9D-E397-410B-AAC2-6ED64F75BB4DQ34338841-63B41D7E-A205-41A0-AF53-EA4BD784B020Q36712113-40E638F7-D4FF-46F5-961D-6AAF31E6ED93Q38363808-A9E7603C-C605-4DC1-B6DF-D77346BA4AD9Q38370133-7F871A2E-B9F0-4FF0-B0EF-B95A9F2C2385Q38378939-2BA65770-4431-4E16-9648-A556EC3E8BE1Q38390663-1CA15254-3434-4175-962C-811A4A3EB659Q38561180-C862C84C-298B-4CB1-B00F-B8A91FE1190DQ38653367-55F0A624-883D-46D3-96D3-AC3CCA3B8D66Q38682952-9C444573-E976-42E8-B90F-3DE25E4C9F41Q38687385-53EF5962-7E76-465E-BFF8-1C9ECB2C2E42Q38742568-8DC89341-C156-4A7F-AA44-62F6CD362B10Q38787388-4754A3B2-AEFE-493E-9D97-5B95A3F6B97DQ38851779-5A6953E6-FE42-4F20-97D2-74E7812C79FAQ38852116-AB872B78-5B6C-4728-AD46-581BFC588EBCQ39200073-A60B59BE-E0B0-40F3-9546-14FEFC12ACDBQ39291412-414D9654-4479-465A-BAC5-0548923DD233Q41846131-59B3DF42-93A7-4E43-8982-331F7A4F6CCDQ46521730-11DC1639-E0B1-48B8-ACD4-22DAEC85C4EBQ46705017-D3BF4A87-8E84-4B44-80CB-9890EA22AEF1Q47425932-F27C402F-458B-4B75-A6F6-7D39CAE92A6CQ47568852-C2B68846-D0AE-4CB7-9802-B2A2DDAEADBEQ47645585-8D31D7D4-FEE6-4BAD-B382-147D75D97944Q47665395-8F0FBDE2-3283-4E9F-B448-B8E165D4C3A9Q47967975-EF1B3AF7-39CC-4DE6-B75C-47868C1247A3
P2860
D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
D-cycloserine augmentation of ...... lot randomized clinical trial.
@en
D-cycloserine augmentation of ...... lot randomized clinical trial.
@nl
type
label
D-cycloserine augmentation of ...... lot randomized clinical trial.
@en
D-cycloserine augmentation of ...... lot randomized clinical trial.
@nl
prefLabel
D-cycloserine augmentation of ...... lot randomized clinical trial.
@en
D-cycloserine augmentation of ...... lot randomized clinical trial.
@nl
P2093
P2860
P356
P1476
D-cycloserine augmentation of ...... lot randomized clinical trial.
@en
P2093
Francis S Lee
Hunter Hoffman
JoAnn Difede
Judith Cukor
Katarzyna Wyka
Margaret Altemus
Megan Olden
P2860
P2888
P304
P356
10.1038/NPP.2013.317
P407
P577
2013-11-12T00:00:00Z
P5875
P6179
1014788255